Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug
Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex (MHC) ‐unrestricted fashion that is independent of the number of tumor mutatio...
Saved in:
Published in | Cancer science Vol. 109; no. 3; pp. 587 - 599 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
John Wiley & Sons, Inc
01.03.2018
John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex (MHC) ‐unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vγ2Vδ2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis‐pivaloyloxymethyl 2‐(thiazole‐2‐ylamino)ethylidene‐1,1‐bisphosphonate (PTA). PTA stimulated the expansion of Vγ2Vδ2 cells to purities up to 99%. These levels were consistently higher than those observed after expansion with zoledronic acid, the most commonly used stimulator for clinical trials. Cell numbers also averaged more than those obtained with zoledronic acid and the expanded Vγ2Vδ2 cells exhibited high cytotoxicity against tumor cells. The high purity of Vγ2Vδ2 cells expanded by PTA increased engraftment success in immunodeficient NOG mice. Even low levels of contaminating αβ T cells resulted in some mice with circulating human αβ T cells rather than Vγ2Vδ2 cells. Vγ2Vδ2 cells from engrafted NOG mice upregulated CD25 and secreted tumor necrosis factor‐α and interferon‐γ in response to PTA‐treated tumor cells. Thus, PTA expands Vγ2Vδ2 T cells to higher purity than zoledronic acid. The high purities allow the successful engraftment of immunodeficient mice without further purification and may speed up the development of allogeneic Vγ2Vδ2 T cell therapies derived from HLA‐matched normal donors for patients with poor autologous Vγ2Vδ2 T cell responses.
Adoptive transfer of Vγ2Vδ2 T cells for treatment of cancer patients has been shown to be safe.In this report, we describe a method for preparing large numbers of highly enriched human Vγ2Vδ2 T cells using a new bisphosphonate prodrug. When the expanded Vγ2Vδ2 cells were administered to immunodeficient mice, the cells remained circulating in the blood for more than 2 weeks and they were functionally active. |
---|---|
AbstractList | Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex (MHC) ‐unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vγ2Vδ2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis‐pivaloyloxymethyl 2‐(thiazole‐2‐ylamino)ethylidene‐1,1‐bisphosphonate (PTA). PTA stimulated the expansion of Vγ2Vδ2 cells to purities up to 99%. These levels were consistently higher than those observed after expansion with zoledronic acid, the most commonly used stimulator for clinical trials. Cell numbers also averaged more than those obtained with zoledronic acid and the expanded Vγ2Vδ2 cells exhibited high cytotoxicity against tumor cells. The high purity of Vγ2Vδ2 cells expanded by PTA increased engraftment success in immunodeficient NOG mice. Even low levels of contaminating αβ T cells resulted in some mice with circulating human αβ T cells rather than Vγ2Vδ2 cells. Vγ2Vδ2 cells from engrafted NOG mice upregulated CD25 and secreted tumor necrosis factor‐α and interferon‐γ in response to PTA‐treated tumor cells. Thus, PTA expands Vγ2Vδ2 T cells to higher purity than zoledronic acid. The high purities allow the successful engraftment of immunodeficient mice without further purification and may speed up the development of allogeneic Vγ2Vδ2 T cell therapies derived from HLA‐matched normal donors for patients with poor autologous Vγ2Vδ2 T cell responses. Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex (MHC) ‐unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vγ2Vδ2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis‐pivaloyloxymethyl 2‐(thiazole‐2‐ylamino)ethylidene‐1,1‐bisphosphonate (PTA). PTA stimulated the expansion of Vγ2Vδ2 cells to purities up to 99%. These levels were consistently higher than those observed after expansion with zoledronic acid, the most commonly used stimulator for clinical trials. Cell numbers also averaged more than those obtained with zoledronic acid and the expanded Vγ2Vδ2 cells exhibited high cytotoxicity against tumor cells. The high purity of Vγ2Vδ2 cells expanded by PTA increased engraftment success in immunodeficient NOG mice. Even low levels of contaminating αβ T cells resulted in some mice with circulating human αβ T cells rather than Vγ2Vδ2 cells. Vγ2Vδ2 cells from engrafted NOG mice upregulated CD25 and secreted tumor necrosis factor‐α and interferon‐γ in response to PTA‐treated tumor cells. Thus, PTA expands Vγ2Vδ2 T cells to higher purity than zoledronic acid. The high purities allow the successful engraftment of immunodeficient mice without further purification and may speed up the development of allogeneic Vγ2Vδ2 T cell therapies derived from HLA‐matched normal donors for patients with poor autologous Vγ2Vδ2 T cell responses. Adoptive transfer of Vγ2Vδ2 T cells for treatment of cancer patients has been shown to be safe.In this report, we describe a method for preparing large numbers of highly enriched human Vγ2Vδ2 T cells using a new bisphosphonate prodrug. When the expanded Vγ2Vδ2 cells were administered to immunodeficient mice, the cells remained circulating in the blood for more than 2 weeks and they were functionally active. Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex (MHC) -unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vγ2Vδ2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate (PTA). PTA stimulated the expansion of Vγ2Vδ2 cells to purities up to 99%. These levels were consistently higher than those observed after expansion with zoledronic acid, the most commonly used stimulator for clinical trials. Cell numbers also averaged more than those obtained with zoledronic acid and the expanded Vγ2Vδ2 cells exhibited high cytotoxicity against tumor cells. The high purity of Vγ2Vδ2 cells expanded by PTA increased engraftment success in immunodeficient NOG mice. Even low levels of contaminating αβ T cells resulted in some mice with circulating human αβ T cells rather than Vγ2Vδ2 cells. Vγ2Vδ2 cells from engrafted NOG mice upregulated CD25 and secreted tumor necrosis factor-α and interferon-γ in response to PTA-treated tumor cells. Thus, PTA expands Vγ2Vδ2 T cells to higher purity than zoledronic acid. The high purities allow the successful engraftment of immunodeficient mice without further purification and may speed up the development of allogeneic Vγ2Vδ2 T cell therapies derived from HLA-matched normal donors for patients with poor autologous Vγ2Vδ2 T cell responses.Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex (MHC) -unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vγ2Vδ2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1-bisphosphonate (PTA). PTA stimulated the expansion of Vγ2Vδ2 cells to purities up to 99%. These levels were consistently higher than those observed after expansion with zoledronic acid, the most commonly used stimulator for clinical trials. Cell numbers also averaged more than those obtained with zoledronic acid and the expanded Vγ2Vδ2 cells exhibited high cytotoxicity against tumor cells. The high purity of Vγ2Vδ2 cells expanded by PTA increased engraftment success in immunodeficient NOG mice. Even low levels of contaminating αβ T cells resulted in some mice with circulating human αβ T cells rather than Vγ2Vδ2 cells. Vγ2Vδ2 cells from engrafted NOG mice upregulated CD25 and secreted tumor necrosis factor-α and interferon-γ in response to PTA-treated tumor cells. Thus, PTA expands Vγ2Vδ2 T cells to higher purity than zoledronic acid. The high purities allow the successful engraftment of immunodeficient mice without further purification and may speed up the development of allogeneic Vγ2Vδ2 T cell therapies derived from HLA-matched normal donors for patients with poor autologous Vγ2Vδ2 T cell responses. Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and kill most types of tumors in a major histocombatibility complex ( MHC ) ‐unrestricted fashion that is independent of the number of tumor mutations. In clinical trials, adoptive transfer of Vγ2Vδ2 T cells has been shown to be safe and does not require preconditioning. In this report, we describe a method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis‐pivaloyloxymethyl 2‐(thiazole‐2‐ylamino)ethylidene‐1,1‐bisphosphonate ( PTA ). PTA stimulated the expansion of Vγ2Vδ2 cells to purities up to 99%. These levels were consistently higher than those observed after expansion with zoledronic acid, the most commonly used stimulator for clinical trials. Cell numbers also averaged more than those obtained with zoledronic acid and the expanded Vγ2Vδ2 cells exhibited high cytotoxicity against tumor cells. The high purity of Vγ2Vδ2 cells expanded by PTA increased engraftment success in immunodeficient NOG mice. Even low levels of contaminating αβ T cells resulted in some mice with circulating human αβ T cells rather than Vγ2Vδ2 cells. Vγ2Vδ2 cells from engrafted NOG mice upregulated CD 25 and secreted tumor necrosis factor‐α and interferon‐γ in response to PTA ‐treated tumor cells. Thus, PTA expands Vγ2Vδ2 T cells to higher purity than zoledronic acid. The high purities allow the successful engraftment of immunodeficient mice without further purification and may speed up the development of allogeneic Vγ2Vδ2 T cell therapies derived from HLA ‐matched normal donors for patients with poor autologous Vγ2Vδ2 T cell responses. |
Author | Kumagai, Asuka Minato, Nagahiro Kamitakahara, Hiroshi Kobayashi, Hirohito Matsumoto, Kenji Toi, Masakazu Iwasaki, Masashi Hayashi, Kosuke Sugie, Tomoharu Morita, Craig T. Murata‐Hirai, Kaoru Okamura, Haruki Wang, Hong Tanaka, Yoshimasa Nada, Mohanad H. |
AuthorAffiliation | 4 Department of Internal Medicine and the Interdisciplinary Graduate Program in Immunology University of Iowa Carver College of Medicine Iowa City Veterans Affairs Health Care System Iowa City IA USA 7 Department of Tumor Immunology and Cell Therapy Hyogo College of Medicine Nishinomiya Hyogo Japan 5 Department of Transfusion Medicine and Cell Processing Tokyo Women's Medical University Tokyo Japan 2 Department of Immunology and Cell Biology Graduate School of Medicine Kyoto University Kyoto Japan 8 Department of Surgery Graduate School of Medicine Kyoto University Kyoto Japan 1 Center for Innovation in Immunoregulative Technology and Therapeutics Graduate School of Medicine Kyoto University Kyoto Japan 3 Center for Bioinformatics and Molecular Medicine Graduate School of Biomedical Sciences Nagasaki University Nagasaki Japan 6 Department of Forest and Biomaterials Science Graduate School of Agriculture Kyoto University Kyoto Japan |
AuthorAffiliation_xml | – name: 1 Center for Innovation in Immunoregulative Technology and Therapeutics Graduate School of Medicine Kyoto University Kyoto Japan – name: 2 Department of Immunology and Cell Biology Graduate School of Medicine Kyoto University Kyoto Japan – name: 5 Department of Transfusion Medicine and Cell Processing Tokyo Women's Medical University Tokyo Japan – name: 7 Department of Tumor Immunology and Cell Therapy Hyogo College of Medicine Nishinomiya Hyogo Japan – name: 4 Department of Internal Medicine and the Interdisciplinary Graduate Program in Immunology University of Iowa Carver College of Medicine Iowa City Veterans Affairs Health Care System Iowa City IA USA – name: 3 Center for Bioinformatics and Molecular Medicine Graduate School of Biomedical Sciences Nagasaki University Nagasaki Japan – name: 6 Department of Forest and Biomaterials Science Graduate School of Agriculture Kyoto University Kyoto Japan – name: 8 Department of Surgery Graduate School of Medicine Kyoto University Kyoto Japan |
Author_xml | – sequence: 1 givenname: Yoshimasa orcidid: 0000-0002-5024-0614 surname: Tanaka fullname: Tanaka, Yoshimasa email: ystanaka@nagasaki-u.ac.jp organization: Nagasaki University – sequence: 2 givenname: Kaoru surname: Murata‐Hirai fullname: Murata‐Hirai, Kaoru organization: Kyoto University – sequence: 3 givenname: Masashi surname: Iwasaki fullname: Iwasaki, Masashi organization: Kyoto University – sequence: 4 givenname: Kenji surname: Matsumoto fullname: Matsumoto, Kenji organization: Kyoto University – sequence: 5 givenname: Kosuke surname: Hayashi fullname: Hayashi, Kosuke organization: Kyoto University – sequence: 6 givenname: Asuka surname: Kumagai fullname: Kumagai, Asuka organization: Nagasaki University – sequence: 7 givenname: Mohanad H. surname: Nada fullname: Nada, Mohanad H. organization: Iowa City Veterans Affairs Health Care System – sequence: 8 givenname: Hong surname: Wang fullname: Wang, Hong organization: Iowa City Veterans Affairs Health Care System – sequence: 9 givenname: Hirohito surname: Kobayashi fullname: Kobayashi, Hirohito organization: Tokyo Women's Medical University – sequence: 10 givenname: Hiroshi surname: Kamitakahara fullname: Kamitakahara, Hiroshi organization: Kyoto University – sequence: 11 givenname: Haruki surname: Okamura fullname: Okamura, Haruki organization: Hyogo College of Medicine – sequence: 12 givenname: Tomoharu surname: Sugie fullname: Sugie, Tomoharu organization: Kyoto University – sequence: 13 givenname: Nagahiro surname: Minato fullname: Minato, Nagahiro organization: Kyoto University – sequence: 14 givenname: Masakazu surname: Toi fullname: Toi, Masakazu organization: Kyoto University – sequence: 15 givenname: Craig T. surname: Morita fullname: Morita, Craig T. organization: Iowa City Veterans Affairs Health Care System |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29288540$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1O3DAUhS1EVWDaBS9QWWLTLgL-S2JvkNAI2kpIXQCLriwnuZkxSuzUTijzXPAcPFM9DEWAhKWra11_OjrXZw9tO-8AoX1KDmk6R7WJh5QLRbfQ7rpnJSHF9uO9zBThbAftxXhNCC-EEh_RDlNMylyQXfT79HYwLlrvsG_xcuqNww93D_f4EtfQdRG3PmDT-GG0N4Bt30_Oj0sIZljhKVq3wAZXNg5Lvy5nRsBD8E2YFp_Qh9Z0ET4_9Rm6Oju9nP_Izn99_zk_Oc9qoRjNSlAVKaocjGglzZMxrkhraCMJFTKNoKhokRNOCGN1o0qSC4DSUF5JlUPLZ-h4oztMVQ9NDW4MptNDsL0JK-2N1a9fnF3qhb_RueRCpj-Zoa9PAsH_mSCOurdxvbxx4KeoqZJMClqIMqEHb9BrPwWX1tOMKUJKyhlP1LcNVQcfY4D22Qwleh2YToHpx8AS--Wl-2fyf0IJONoAf20Hq_eV9PzkYiP5D5Y6owM |
CitedBy_id | crossref_primary_10_1038_s41423_020_0504_x crossref_primary_10_3389_fimmu_2023_1282710 crossref_primary_10_4155_fmc_2018_0591 crossref_primary_10_1111_cei_13436 crossref_primary_10_3389_fimmu_2022_920888 crossref_primary_10_1111_imr_12917 crossref_primary_10_1128_spectrum_03614_23 crossref_primary_10_1016_j_jim_2019_01_003 crossref_primary_10_1016_j_isci_2023_107802 crossref_primary_10_3390_cells13020128 crossref_primary_10_1002_cmdc_202000198 crossref_primary_10_3390_cells11182816 crossref_primary_10_3389_fimmu_2018_01246 crossref_primary_10_1039_D0MD00221F crossref_primary_10_2174_1389201020666190206203640 crossref_primary_10_3389_fimmu_2022_1065495 crossref_primary_10_3390_cancers12041014 crossref_primary_10_3390_cancers13040598 crossref_primary_10_3389_fimmu_2020_01405 crossref_primary_10_3389_fimmu_2024_1336870 crossref_primary_10_1039_D1MD00297J crossref_primary_10_3390_ijms241310873 crossref_primary_10_3390_ijms21144877 crossref_primary_10_3389_fimmu_2018_02528 crossref_primary_10_1016_j_lfs_2021_119066 crossref_primary_10_3389_fimmu_2022_872122 crossref_primary_10_1155_2018_5081634 crossref_primary_10_3389_fimmu_2023_1058838 crossref_primary_10_1126_scitranslmed_aaz3426 crossref_primary_10_1016_j_ejps_2023_106571 crossref_primary_10_37349_ei_2022_00066 crossref_primary_10_1080_2162402X_2021_1989789 crossref_primary_10_1002_wsbm_1643 crossref_primary_10_1016_j_htct_2021_09_007 |
Cites_doi | 10.1056/NEJMoa1200694 10.1097/CJI.0b013e318207ecfb 10.1182/blood-2016-01-628982 10.4049/jimmunol.145.9.2827 10.1124/mol.105.020776 10.1158/1535-7163.MCT-17-0386 10.4049/jimmunol.170.7.3696 10.1002/eji.201040959 10.1007/s00262-011-1021-7 10.1056/NEJMoa1200690 10.1016/j.jcyt.2012.12.004 10.1038/375155a0 10.1158/1078-0432.CCR-17-1439 10.1097/TP.0b013e3181a5cb07 10.1038/nm.4015 10.1093/intimm/dxm031 10.1016/S0014-5793(01)03191-X 10.1111/j.1600-065X.2006.00479.x 10.1016/j.exphem.2009.04.008 10.1038/s41598-017-05553-0 10.1002/cam4.196 10.1182/blood-2012-05-430470 10.1371/journal.pone.0044219 10.5402/2012/195727 10.4049/jimmunol.1002697 10.4049/jimmunol.1300658 10.4049/jimmunol.1500314 10.3109/14653249.2010.515581 10.1074/jbc.M112.384354 10.1016/j.apsb.2015.07.003 10.1007/s00262-008-0491-8 10.1038/ni.3795 10.1084/jem.20021500 10.1038/nm0596-551 10.1002/cmdc.201700626 10.4049/jimmunol.154.3.998 10.1126/science.aaa1348 10.1186/s40425-017-0209-6 10.1038/nature12477 10.1038/bjc.2011.293 10.1111/j.1365-3083.1992.tb02946.x 10.1016/j.immuni.2014.03.003 10.1002/cmdc.201600465 10.1002/eji.1830211215 10.1073/pnas.91.17.8175 |
ContentType | Journal Article |
Copyright | 2017 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2017 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ HCIFZ LK8 M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1111/cas.13491 |
DatabaseName | Wiley Online Library Open Access Wiley Online Library Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest One Academic MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | TANAKA et al |
EISSN | 1349-7006 |
EndPage | 599 |
ExternalDocumentID | 10_1111_cas_13491 29288540 CAS13491 |
Genre | article Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GrantInformation_xml | – fundername: Ministry of Education, Science, Culture, Sports, and Technology of Japan funderid: 17933802 – fundername: Platform Project for Supporting Drug Discovery and Life Science Research – fundername: Kyoto University funderid: 11800121 – fundername: Department of Veterans Affairs – fundername: Astellas Pharma – fundername: Grants‐in‐Aid for Scientific Research funderid: 16K08844 – fundername: Japan Agency for Medical Research and Development – fundername: National Cancer Institute funderid: 1 I01 BX000972‐01A1 – fundername: University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence funderid: CA097274; P30CA086862 – fundername: BLRD VA grantid: I01 BX000972 – fundername: NCI NIH HHS grantid: P30 CA086862 – fundername: University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence grantid: CA097274; P30CA086862 – fundername: Kyoto University grantid: 11800121 – fundername: Grants‐in‐Aid for Scientific Research grantid: 16K08844 – fundername: Ministry of Education, Science, Culture, Sports, and Technology of Japan grantid: 17933802 – fundername: National Cancer Institute grantid: 1 I01 BX000972‐01A1 |
GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACSCC ACXQS ADBBV ADKYN ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT CGR CUY CVF ECM EIF ITC NPM AAYXX CITATION ABUWG AZQEC DWQXO GNUQQ PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c4921-7e9b06b5ea4f815928390fa1d80148f81e6b165030022cd97054ee7a13b895ef3 |
IEDL.DBID | RPM |
ISSN | 1347-9032 1349-7006 |
IngestDate | Tue Sep 17 21:17:04 EDT 2024 Sat Jul 20 16:38:37 EDT 2024 Fri Sep 13 08:51:53 EDT 2024 Thu Sep 26 15:41:47 EDT 2024 Wed Oct 09 10:19:03 EDT 2024 Sat Aug 24 00:59:05 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Vγ2Vδ2 T cells bisphosphonate adoptive cancer immunotherapy farnesyl diphosphate synthase zoledronic acid |
Language | English |
License | Attribution-NonCommercial 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4921-7e9b06b5ea4f815928390fa1d80148f81e6b165030022cd97054ee7a13b895ef3 |
Notes | Funding information This study was supported by grants from the Ministry of Education, Science, Culture, Sports, and Technology of Japan. To Y. Tanaka: Grants‐in‐Aid for Scientific Research, 16K08844, and Platform Project for Supporting Drug Discovery and Life Science Research, 17933802, from Ministry of Education, Science, Culture, Sports, and Technology of Japan and Astellas Pharma. To Y. Tanaka: “Special Coordination Funds for Promoting Science and Technologies” program through the “Formation of Center for Innovation by Fusion of Advanced Technologies”, 11800121, from Kyoto University and Japan Agency for Medical Research and Development. To Y. Tanaka: Grants‐in‐Aid for Translational Research, A48 and A90), from the Department of Veterans Affairs. To C. T. Morita: Veterans Health Administration, 1 I01 BX000972‐01A1, and from the National Cancer Institute. To C. T. Morita: CA097274 (University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence) and P30CA086862 (Core Support). C. T Morita is the Kelting Family Scholar in Rheumatology. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Toi and Morita authors contributed equally to this work. |
ORCID | 0000-0002-5024-0614 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834800/ |
PMID | 29288540 |
PQID | 2290071323 |
PQPubID | 4378882 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5834800 proquest_miscellaneous_1982841647 proquest_journals_2290071323 crossref_primary_10_1111_cas_13491 pubmed_primary_29288540 wiley_primary_10_1111_cas_13491_CAS13491 |
PublicationCentury | 2000 |
PublicationDate | March 2018 |
PublicationDateYYYYMMDD | 2018-03-01 |
PublicationDate_xml | – month: 03 year: 2018 text: March 2018 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Tokyo – name: Hoboken |
PublicationTitle | Cancer science |
PublicationTitleAlternate | Cancer Sci |
PublicationYear | 2018 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
References | 2017; 5 2007; 19 2017; 7 2012; 120 2012; 287 2012; 2012 2015; 5 2009; 87 2012; 366 2011; 60 2013; 500 2017; 23 2008; 57 2003; 170 2011; 13 2011; 34 1992; 36 2016; 127 2015; 348 1995; 375 2001; 509 1990; 145 2014; 40 1995; 154 2003; 197 2016; 11 2015; 195 2011; 105 2013; 15 2007; 215 2014; 3 1991; 21 2017; 16 2006; 69 2017; 12 2011; 41 1964; 55 2017; 18 2013; 191 1994; 91 2012; 7 1996; 2 2010; 30 2009; 37 2011; 187 2016; 22 e_1_2_6_32_1 e_1_2_6_30_1 Okawaki M (e_1_2_6_26_1) 2014; 40 e_1_2_6_19_1 Kabelitz D (e_1_2_6_47_1) 1990; 145 e_1_2_6_13_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_17_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_43_1 e_1_2_6_20_1 e_1_2_6_41_1 e_1_2_6_9_1 e_1_2_6_5_1 e_1_2_6_7_1 e_1_2_6_24_1 e_1_2_6_49_1 e_1_2_6_3_1 e_1_2_6_22_1 e_1_2_6_45_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_50_1 Kobayashi H (e_1_2_6_28_1) 2010; 30 Hakomori S (e_1_2_6_36_1) 1964; 55 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_12_1 e_1_2_6_33_1 Bukowski JF (e_1_2_6_18_1) 1995; 154 e_1_2_6_39_1 Kakimi K (e_1_2_6_29_1) 2014; 3 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_42_1 e_1_2_6_21_1 e_1_2_6_40_1 e_1_2_6_8_1 e_1_2_6_4_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_48_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_44_1 e_1_2_6_27_1 e_1_2_6_46_1 |
References_xml | – volume: 13 start-page: 92 year: 2011 end-page: 97 article-title: Zoledronate‐activated Vγ9γδ T cell‐based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors publication-title: Cytotherapy – volume: 91 start-page: 8175 year: 1994 end-page: 8179 article-title: Nonpeptide ligands for human γδ T cells publication-title: Proc Natl Acad Sci USA – volume: 195 start-page: 4583 year: 2015 end-page: 4594 article-title: Sensor function for butyrophilin 3A1 in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T Cells publication-title: J Immunol – volume: 36 start-page: 107 year: 1992 end-page: 117 article-title: Reactivity of γδ T cells induced by the tumour cell line RPMI 8226: functional heterogeneity of clonal populations and role of GroEL heat shock proteins publication-title: Scand J Immunol – volume: 509 start-page: 317 year: 2001 end-page: 322 article-title: Identification of ( )‐4‐hydroxy‐3‐methyl‐but‐2‐enyl pyrophosphate as a major activator for human γδ T cells in publication-title: FEBS Lett – volume: 21 start-page: 2999 year: 1991 end-page: 3007 article-title: Functionally distinct subsets of human γ/δ T cells publication-title: Eur J Immunol – volume: 191 start-page: 1029 year: 2013 end-page: 1042 article-title: Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells publication-title: J Immunol – volume: 60 start-page: 1075 year: 2011 end-page: 1084 article-title: Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL‐2 to patients with advanced renal cell carcinoma publication-title: Cancer Immunol Immunother – volume: 69 start-page: 1624 year: 2006 end-page: 1632 article-title: Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid‐phase endocytosis publication-title: Mol Pharmacol – volume: 16 start-page: 2598 year: 2017 end-page: 2608 article-title: Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers publication-title: Mol Cancer Ther – volume: 55 start-page: 205 year: 1964 end-page: 208 article-title: A rapid permethylation of glycolipid, and polysaccharide catalyzed by methylsulfinyl carbanion in dimethyl sulfoxide publication-title: J Biochem – volume: 5 start-page: 442 year: 2015 end-page: 453 article-title: Insoluble drug delivery strategies: review of recent advances and business prospects publication-title: Acta Pharm Sin B – volume: 215 start-page: 59 year: 2007 end-page: 76 article-title: Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens publication-title: Immunol Rev – volume: 40 start-page: 490 year: 2014 end-page: 500 article-title: The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells publication-title: Immunity – volume: 105 start-page: 778 year: 2011 end-page: 786 article-title: Clinical evaluation of autologous T cell‐based immunotherapy for metastatic solid tumours publication-title: Br J Cancer – volume: 127 start-page: 3331 year: 2016 end-page: 3340 article-title: T cells for viral infections after allogeneic hematopoietic stem cell transplant publication-title: Blood – volume: 187 start-page: 5099 year: 2011 end-page: 5113 article-title: Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism publication-title: J Immunol – volume: 34 start-page: 202 year: 2011 end-page: 211 article-title: Adoptive immunotherapy for advanced non‐small cell lung cancer using zoledronate‐expanded γδ T cells: a phase I clinical study publication-title: J Immunother – volume: 18 start-page: 1046 year: 2017 end-page: 1057 article-title: Translation is actively regulated during the differentiation of CD8 effector T cells publication-title: Nat Immunol – volume: 500 start-page: 415 year: 2013 end-page: 421 article-title: Signatures of mutational processes in human cancer publication-title: Nature – volume: 375 start-page: 155 year: 1995 end-page: 158 article-title: Natural and synthetic non‐peptide antigens recognized by human γδ T cells publication-title: Nature – volume: 87 start-page: 1654 year: 2009 end-page: 1658 article-title: Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice publication-title: Transplantation – volume: 170 start-page: 3696 year: 2003 end-page: 3706 article-title: Conservation of nonpeptide antigen recognition by rhesus monkey Vγ2Vδ2 T cells publication-title: J Immunol – volume: 366 start-page: 2443 year: 2012 end-page: 2454 article-title: Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer publication-title: N Engl J Med – volume: 37 start-page: 956 year: 2009 end-page: 968 article-title: Clinical and immunological evaluation of zoledronate‐activated Vγ9γδ T‐cell‐based immunotherapy for patients with multiple myeloma publication-title: Exp Hematol – volume: 287 start-page: 32780 year: 2012 end-page: 32790 article-title: The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin‐3 (BTN3A)‐specific antibodies publication-title: J Biol Chem – volume: 5 start-page: 9 year: 2017 article-title: Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation publication-title: J Immunother Cancer – volume: 41 start-page: 345 year: 2011 end-page: 355 article-title: Expression and function of PD‐1 in human γδ T cells that recognize phosphoantigens publication-title: Eur J Immunol – volume: 197 start-page: 163 year: 2003 end-page: 168 article-title: Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells publication-title: J Exp Med – volume: 3 start-page: 362 year: 2014 end-page: 375 article-title: Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer publication-title: Cancer Med – volume: 7 start-page: e44219 year: 2012 article-title: Xenogeneic graft‐versus‐host‐disease in NOD‐scid IL‐2Rγ mice display a T‐effector memory phenotype publication-title: PLoS One – volume: 3 start-page: 23 year: 2014 end-page: 33 article-title: γδ T cell therapy for the treatment of non‐small cell lung cancer publication-title: Transl Lung Cancer Res – volume: 7 start-page: 5987 year: 2017 article-title: Anti‐tumor activity and immunotherapeutic potential of a bisphosphonate prodrug publication-title: Sci Rep – volume: 15 start-page: 481 year: 2013 end-page: 491 article-title: Ex vivo characterization of γδ T‐cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin‐2 receptor β‐chain and the common γ‐chain publication-title: Cytotherapy – volume: 12 start-page: 2006 year: 2017 end-page: 2013 article-title: Live cell labeling with terpyridine derivative proligands to measure cytotoxicity mediated by immune cells publication-title: ChemMedChem – volume: 23 start-page: 5729 year: 2017 end-page: 5736 article-title: Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor‐based immunotherapy publication-title: Clin Cancer Res – volume: 120 start-page: 2269 year: 2012 end-page: 2279 article-title: Key implication of CD277/butyrophilin‐3 (BTN3A) in cellular stress sensing by a major human γδ T‐cell subset publication-title: Blood – volume: 40 start-page: 33 year: 2014 end-page: 39 article-title: Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer publication-title: Kawasaki Med J – volume: 19 start-page: 657 year: 2007 end-page: 673 article-title: Preferential recognition of a microbial metabolite by human Vγ2Vδ2 T cells publication-title: Int Immunol – volume: 154 start-page: 998 year: 1995 end-page: 1006 article-title: Vγ2Vδ2 TCR‐dependent recognition of non‐peptide antigens and Daudi cells analyzed by TCR gene transfer publication-title: J Immunol – volume: 145 start-page: 2827 year: 1990 end-page: 2832 article-title: Human cytotoxic lymphocytes. V. Frequency and specificity of γδ cytotoxic lymphocyte precursors activated by allogeneic or autologous stimulator cells publication-title: J Immunol – volume: 30 start-page: 575 year: 2010 end-page: 579 article-title: Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T‐cells in a patient with renal cell carcinoma publication-title: Anticancer Res – volume: 348 start-page: 124 year: 2015 end-page: 128 article-title: Mutational landscape determines sensitivity to PD‐1 blockade in non‐small cell lung cancer publication-title: Science – volume: 11 start-page: 2656 year: 2016 end-page: 2663 article-title: Targeting cancer cells with a bisphosphonate prodrug publication-title: ChemMedChem – volume: 22 start-page: 26 year: 2016 end-page: 36 article-title: Prospects for gene‐engineered T cell immunotherapy for solid cancers publication-title: Nat Med – volume: 366 start-page: 2455 year: 2012 end-page: 2465 article-title: Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer publication-title: N Engl J Med – volume: 2 start-page: 551 year: 1996 end-page: 555 article-title: Long‐term restoration of immunity against Epstein‐Barr virus infection by adoptive transfer of gene‐modified virus‐specific T lymphocytes publication-title: Nat Med – volume: 57 start-page: 1599 year: 2008 end-page: 1609 article-title: Phase‐I study of Innacell γδ, an autologous cell‐therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL‐2, in patients with metastatic renal cell carcinoma publication-title: Cancer Immunol Immunother – volume: 2012 start-page: 195727 year: 2012 article-title: Drug solubility: importance and enhancement techniques publication-title: ISRN Pharm – ident: e_1_2_6_3_1 doi: 10.1056/NEJMoa1200694 – volume: 55 start-page: 205 year: 1964 ident: e_1_2_6_36_1 article-title: A rapid permethylation of glycolipid, and polysaccharide catalyzed by methylsulfinyl carbanion in dimethyl sulfoxide publication-title: J Biochem contributor: fullname: Hakomori S – ident: e_1_2_6_23_1 doi: 10.1097/CJI.0b013e318207ecfb – ident: e_1_2_6_48_1 doi: 10.1182/blood-2016-01-628982 – volume: 145 start-page: 2827 year: 1990 ident: e_1_2_6_47_1 article-title: Human cytotoxic lymphocytes. V. Frequency and specificity of γδ+ cytotoxic lymphocyte precursors activated by allogeneic or autologous stimulator cells publication-title: J Immunol doi: 10.4049/jimmunol.145.9.2827 contributor: fullname: Kabelitz D – ident: e_1_2_6_32_1 doi: 10.1124/mol.105.020776 – ident: e_1_2_6_5_1 doi: 10.1158/1535-7163.MCT-17-0386 – volume: 30 start-page: 575 year: 2010 ident: e_1_2_6_28_1 article-title: Complete remission of lung metastasis following adoptive immunotherapy using activated autologous γδ T‐cells in a patient with renal cell carcinoma publication-title: Anticancer Res contributor: fullname: Kobayashi H – ident: e_1_2_6_50_1 doi: 10.4049/jimmunol.170.7.3696 – ident: e_1_2_6_35_1 doi: 10.1002/eji.201040959 – ident: e_1_2_6_22_1 doi: 10.1007/s00262-011-1021-7 – ident: e_1_2_6_2_1 doi: 10.1056/NEJMoa1200690 – ident: e_1_2_6_24_1 doi: 10.1016/j.jcyt.2012.12.004 – ident: e_1_2_6_10_1 doi: 10.1038/375155a0 – ident: e_1_2_6_7_1 doi: 10.1158/1078-0432.CCR-17-1439 – ident: e_1_2_6_46_1 doi: 10.1097/TP.0b013e3181a5cb07 – ident: e_1_2_6_8_1 doi: 10.1038/nm.4015 – ident: e_1_2_6_12_1 doi: 10.1093/intimm/dxm031 – ident: e_1_2_6_11_1 doi: 10.1016/S0014-5793(01)03191-X – ident: e_1_2_6_9_1 doi: 10.1111/j.1600-065X.2006.00479.x – ident: e_1_2_6_20_1 doi: 10.1016/j.exphem.2009.04.008 – ident: e_1_2_6_34_1 doi: 10.1038/s41598-017-05553-0 – ident: e_1_2_6_25_1 doi: 10.1002/cam4.196 – ident: e_1_2_6_13_1 doi: 10.1182/blood-2012-05-430470 – ident: e_1_2_6_45_1 doi: 10.1371/journal.pone.0044219 – ident: e_1_2_6_39_1 doi: 10.5402/2012/195727 – ident: e_1_2_6_31_1 doi: 10.4049/jimmunol.1002697 – volume: 40 start-page: 33 year: 2014 ident: e_1_2_6_26_1 article-title: Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer publication-title: Kawasaki Med J contributor: fullname: Okawaki M – ident: e_1_2_6_14_1 doi: 10.4049/jimmunol.1300658 – ident: e_1_2_6_17_1 doi: 10.4049/jimmunol.1500314 – ident: e_1_2_6_27_1 doi: 10.3109/14653249.2010.515581 – ident: e_1_2_6_15_1 doi: 10.1074/jbc.M112.384354 – ident: e_1_2_6_40_1 doi: 10.1016/j.apsb.2015.07.003 – ident: e_1_2_6_19_1 doi: 10.1007/s00262-008-0491-8 – ident: e_1_2_6_44_1 doi: 10.1038/ni.3795 – ident: e_1_2_6_30_1 doi: 10.1084/jem.20021500 – ident: e_1_2_6_49_1 doi: 10.1038/nm0596-551 – ident: e_1_2_6_38_1 doi: 10.1002/cmdc.201700626 – volume: 154 start-page: 998 year: 1995 ident: e_1_2_6_18_1 article-title: Vγ2Vδ2 TCR‐dependent recognition of non‐peptide antigens and Daudi cells analyzed by TCR gene transfer publication-title: J Immunol doi: 10.4049/jimmunol.154.3.998 contributor: fullname: Bukowski JF – ident: e_1_2_6_4_1 doi: 10.1126/science.aaa1348 – ident: e_1_2_6_37_1 doi: 10.1186/s40425-017-0209-6 – ident: e_1_2_6_6_1 doi: 10.1038/nature12477 – ident: e_1_2_6_21_1 doi: 10.1038/bjc.2011.293 – ident: e_1_2_6_42_1 doi: 10.1111/j.1365-3083.1992.tb02946.x – ident: e_1_2_6_16_1 doi: 10.1016/j.immuni.2014.03.003 – volume: 3 start-page: 23 year: 2014 ident: e_1_2_6_29_1 article-title: γδ T cell therapy for the treatment of non‐small cell lung cancer publication-title: Transl Lung Cancer Res contributor: fullname: Kakimi K – ident: e_1_2_6_33_1 doi: 10.1002/cmdc.201600465 – ident: e_1_2_6_41_1 doi: 10.1002/eji.1830211215 – ident: e_1_2_6_43_1 doi: 10.1073/pnas.91.17.8175 |
SSID | ssj0036494 |
Score | 2.435654 |
Snippet | Cancer immunotherapy with human γδ T cells expressing Vγ2Vδ2 T cell receptor (also termed Vγ9Vδ2) has shown promise because of their ability to recognize and... |
SourceID | pubmedcentral proquest crossref pubmed wiley |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 587 |
SubjectTerms | adoptive cancer immunotherapy Adoptive immunotherapy Adoptive transfer Animals bisphosphonate Bisphosphonates Breast cancer Breast Neoplasms - immunology Breast Neoplasms - therapy Cancer immunotherapy Cancer therapies CD25 antigen Clinical trials Cytotoxicity Diphosphonates - administration & dosage Diphosphonates - chemistry Diphosphonates - pharmacology farnesyl diphosphate synthase Female Histocompatibility antigen HLA Humans Immunodeficiency Immunotherapy Immunotherapy, Adoptive Interferon Inventors Kidney cancer Lung cancer Lymphocytes Lymphocytes T Major histocompatibility complex Male Melanoma Metabolites Metastasis Mice Mutation Original Prodrugs - administration & dosage Prodrugs - pharmacology Prostate cancer Prostatic Neoplasms - immunology Prostatic Neoplasms - therapy Purification Receptors, Antigen, T-Cell, gamma-delta - metabolism T cell receptors T-Lymphocytes - immunology T-Lymphocytes - transplantation Treatment Outcome Tumor cells Tumors Viral infections Vγ2Vδ2 T cells Xenograft Model Antitumor Assays Zoledronic acid |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTtwwEB5RkKpeKmhpCX9yKw5cot3EdmyfEKBFq0qgqoBET5GdOLCXZMvuSvBc8Bw8EzP52bJCcIgUxYkSz8Tjb8bjbwD2jOLWmyjHgRTnochNEWrr0Fnh_QJnT6l8TZJ0epYML8WvK3m1BMNuLwylVXY2sTbUeZVRjLxHvOTkUcW8Zx1FAbJp72D8L6T6UbTO2hbT-AArcSRowXblaHD2-09nlXkiTFPgVqjQ9HncsgxRVg8VFyOWvmhxbnoFOF_nTb7Es_WEdLIKn1skyQ4b1a_Bki-_wMfTdq38K_wd3OFIp2AYqwpW1-JjTw9Pj-yCUbR-whCuMptXYzJ4bET7RNrdWPeMsuGvmWVuNBnfVHSUiEkZWdvb2fU6XJ4MLo6HYVtIIcyEiaNQeeP6iZPeikKjBhBSmH5ho5yoYzRe8omLEKpxmtGz3CjEcd4rG3GnjfQF_wbLZVX6DWA8MdJkiTQO_bgoU1ZmeeESlRQS0YTWAfzsRJiOG76MtPMzUM5pLecAtjvhpu2QmaT_FRzAj3kz_uwkE1v6aoZPG3QQBVGgBfC90cX8LTF2SyP-DEAtaGl-AxFpL7aUo5uaUFtqLhA4B7Bf6_PtD0-PD8_rk833e7AFnxBY6SZXbRuWp7czv4PgZep22__yGbb67yY priority: 102 providerName: ProQuest – databaseName: Wiley Online Library - Core collection (SURFmarket) dbid: DR2 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS-UwEB7EB_Fl19vudr0Ql33wpXLaNE2CTyKKCPrgBRSEkrSpHhbag-cccPdvub_D37Qz6QWPIiw-FEqT0iSTmXyTTr4B-KklN05HBSpSXIRJoctQGYvOCh-UuHoK6TxJ0ulZenyVnFyL6znY687CNPwQ_YYbaYa316Tgxo5fKDmlBCNuPXJ9iEiPANF5Tx3F00Q3CW0TGeoBj1tWIYri6d-cXYveAMy3cZIv8atfgI4-w23X9Cbu5NfudGJ38z-vWB0_2Lcl-NQCU7bfzKRlmHPVCiyctr_eV-Hm8BENB-2tsbpkPrUfe356_ssuGW3-jxmiX2aKekT2kw3p2El7uOs3o-D6O2aYHY5H9zVdFUJcRsb7YXq3BldHh5cHx2GblyHMEx1HoXTaDlIrnElKhQJFhKIHpYkKYqJR-MilNkLkxwkg5IWWCAudkybiVmnhSv4F5qu6ct-A8VQLnadCW3QLo1wakRelTWVaCgQnSgXwo5NQNmroN7LObcFByvwgBbDRyS5rNXCcEY89eeAxD2C7L0bdoTExlaun-LZGfzMhRrUAvjai7r8SY7cUwtkA5Mwk6CsQL_dsSTW89_zcQvEEcXgAO17G7zc8O9i_8Dff_7_qOiwiZlNNGNwGzE8epm4TcdHEbnkF-AcR1wom priority: 102 providerName: Wiley-Blackwell |
Title | Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.13491 https://www.ncbi.nlm.nih.gov/pubmed/29288540 https://www.proquest.com/docview/2290071323/abstract/ https://www.proquest.com/docview/1982841647/abstract/ https://pubmed.ncbi.nlm.nih.gov/PMC5834800 |
Volume | 109 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NatwwEB6yKZReStNft-milh56cXZtSZZ0TJcNobBhSRNIT0ay5WQhsZdsFtrnap8jz9QZ2V4SQi492Bj_IDEzkr4Zj74B-GIUt94kJQ6ktIxFaapYW4fOCh9XuHpK5QNJ0uwoOzwV38_k2RbIfi9MSNov3GKvvrzaqxcXIbdyeVWM-jyx0Xw2kZoLBDqjAQwU572L3k6_PBOmrWQrVGzGPO3ohCh9h6qIER0flYdJTap1iHncXY8egMyHuZJ3MWxYhA5ewPMOPbL9tpc7sOXrl_B01v0ffwU_p79wdFMAjDUVC_X32O2f27_shFGEfsUQojJbNkua5NiC9oZ0O7B-M8qAP2eWucVqedHQUSMOZTTDXq_PX8PpwfRkchh3xRPiQpg0iZU3bpw56a2oNEodYYQZVzYpiS5G4y2fuQThGadVvCiNQuzmvbIJd9pIX_E3sF03tX8HjGdGmiKTxqHvlhTKyqKsXKaySiKC0DqCz70I82XLkZH3vgWKPA8ij2C3F27eDZNVTmTz5CanPIJPm8do4CQTW_tmjV8bdAoF0Z5F8LbVxaaVXokRqHta2rxA5Nn3n6BNBRLtzoYi-Br0-XjH88n-j3Dx_r8b-QDPEGfpNnVtF7Zvrtf-I2KZGzeEQSrmQ3jybXo0Px6GiACdj9NhsOp_GHP3Zg |
link.rule.ids | 230,315,733,786,790,870,891,1382,11589,21416,27957,27958,33779,33780,43840,46087,46329,46511,46753,50849,50958,53827,53829,74659 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwEB7BVgIuqPyV0AIGceASsYnt2D6httpqge4KwVYqp8hOnHYvydLtSvBc9Dn6TMwkzsKqgkOkKE6UeCYefzMefwPwxihuvUlKHEhpGYvSVLG2Dp0VPqxw9pTKtyRJk2k2PhEfT-VpCLgtQ1plbxNbQ102BcXI3xEvOXlUKX-_-B5T1ShaXQ0lNG7DluDoqgxg62A0_fylt8U8E6YraytUbIY8DdxClMtDJcWImy_ZnJFuwMyb2ZJ_o9h2GjrahvsBP7L9TuEP4JavH8KdSVghfwTfRj9wfFMIjDUVayvwsetf11dsxihGv2QIUpktmwWZOTan3SFhD9ZPRjnwZ8wyN18uzhs6akSijGzsxersMZwcjWaH4ziUT4gLYdIkVt64Yeakt6LSKHcEEmZY2aQkwhiNl3zmEgRonObxojQK0Zv3yibcaSN9xZ_AoG5q_xQYz4w0RSaNQ-8tKZSVRVm5TGWVRAyhdQSvexHmi44lI--9C5Rz3so5gr1euHkYKMv8j1ojeLVuxl-cZGJr36zwaYNuoSDiswh2Ol2s35JitzSizgjUhpbWNxB99mZLPT9vabSl5gLhcgRvW33--8Pzw_2v7cmz__fgJdwdzybH-fGH6adduIfQSnfZanswuLxY-ecIXy7di_CP_gaV2O5Z |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwEB5BK1VcEP8NFDCIA5eom9iO7RMqZVflp6sKWqmcIjux270kS7crwXPBc_SZmEmchVUFh0hRnCjxzHj8jT35BuCVUdx6k9U4kPI6FbUJqbYOgxU-Cjh7SuU7kqTDaXFwIj6cytOY_7SIaZWDT-wcdd1WtEa-S7zkFFHlfDfEtIijd5M3828pVZCindZYTuMmbCpRSLTwzbfj6dHnwS_zQpi-xK1QqRnxPPIMUV4PlRcjnr5sfXa6BjmvZ07-jWi7KWlyB25HLMn2euXfhRu-uQdbh3G3_D58HX_HsU7LYawNrKvGx65-Xv1ix4zW6xcMASuzdTsnl8dm9KdI_B_rB6N8-DNmmZst5uctHQ2iUkb-9mJ59gBOJuPj_YM0llJIK2HyLFXeuFHhpLciaNQBggozCjariTxG4yVfuAzBGqc5vaqNQiTnvbIZd9pIH_hD2Gjaxm8D44WRpkIBO4zkskpZWdXBFaoIEvGE1gm8HERYznvGjHKINFDOZSfnBHYG4ZZx0CzKPypO4MWqGc2dZGIb3y7xaYMhoiAStAQe9bpYvSXHbmlEoAmoNS2tbiAq7fWWZnbeUWpLzQVC5wRed_r894eX-3tfupPH_-_Bc9hC8yw_vZ9-fAK3EGXpPnFtBzYuL5b-KSKZS_csmuhvxpnylg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Expansion+of+human+%CE%B3%CE%B4+T+cells+for+adoptive+immunotherapy+using+a+bisphosphonate+prodrug&rft.jtitle=Cancer+science&rft.au=Tanaka%2C+Yoshimasa&rft.au=Kaoru+Murata%E2%80%90Hirai&rft.au=Iwasaki%2C+Masashi&rft.au=Matsumoto%2C+Kenji&rft.date=2018-03-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=109&rft.issue=3&rft.spage=587&rft.epage=599&rft_id=info:doi/10.1111%2Fcas.13491&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |